ITM Isotope Technologies Munich SE

Celebrating 20 years of ITM means celebrating our people – the driving force behind our success! 🎉 Over the past two decades, our team has grown to an impressive 750 strong with each person contributing to ITM's journey and #culture. We're excited to share a new video that brings our #growth to life, as colleagues hold signs marking the year they joined ITM. Together, they create a powerful visual of #passion, #teamwork, and #individuality that defines who we are. Every year tells a story, and so does each and every ITM team member. Here’s to many more milestones ahead! 🌍 🎥 Watch the video and celebrate with us - 20 years of passion for people!

As we wrap up another successful European Association of Nuclear Medicine (EANM) conference, ITM extends our deepest gratitude to all our guests and industry partners who visited our booth. Your excitement in ITM, the #Radiopharmaceutical industry and the engaging conversations we shared made this event truly special. A special thanks to Key Opinion Leaders Karolien Goffin and Ken Herrmann for their insightful contributions — be sure to check out our article highlighting their key moments and video highlights! https://lnkd.in/guuQzNeN At ITM, building and strengthening collaborations is at the core of everything we do. These partnerships are essential in driving innovation to help improve the lives of patients. Thank you for being part of our journey! #EANM2024 #Collaboration #Innovation #NuclearMedicine #CancerTherapy #Theranostics

We are proud to announce a significant step forward in our partnership with Technische Universität München and TUM University Hospital (MRI)! Together, we have signed a new framework agreement to advance innovative #radiopharmaceutical treatments for #cancer. This agreement builds on our many years of successful collaboration, aiming to accelerate the development of nuclear medicine by uniting TUM’s cutting-edge research, MRI’s renowned clinical expertise, and ITM’s expertise in #radioisotope production and radiopharmaceutical development. Thank you Prof. Thomas F. Hofmann, President of TUM, and Prof. Dr. med. Stephanie E. Combs, Dean of TUM University Hospital, for the thoughtful discussions and for visiting us and touring our #NOVA production facility.

In our #EANM video series, we invited two nuclear medicine experts, Karolien Goffin and Ken Herrmann, to discuss the most exciting developments from each day from the Annual Congress of the European Association of Nuclear Medicine (EANM) 2024, right from the vibrant city of Hamburg, Germany. As all great journeys must eventually reach their destination, the incredible #EANM2024 has come to an end! Check out our LinkedIn article to see all the highlight episodes from the last few days, as well as a new video from Karolien Goffin and Ken Herrmann sharing their top three highlights from this year's event. Have fun watching the videos and mark your calendars – the #EANM2025 is set to take place in the stunning city of Barcelona from October 4-8! 

What an exhilarating day yesterday at the European Association of Nuclear Medicine (EANM) Congress 2024! Karolien Goffin and Ken Herrmann are back with us, sharing their invaluable insights. The day was filled with groundbreaking abstracts focused on metastatic #prostate cancer and #neuroendocrine tumors. The conversations were electric, especially around the innovative trends shaping the future of #nuclearmedicine. Enthusiastic discussions on #artificialintelligence and the proactive steps taken at the #EuropeanUnion stage to ensure a sustainable future for the field left everyone inspired! Our experts also had some uplifting words for the young professionals eager to carve out their niche in nuclear medicine. Be sure to tune in tomorrow as they wrap up the final day of the congress with more thrilling updates and insights. Auf Wiedersehen! #theranostics #Radiodiagnostic #TargetedRadiopharmaceuticalTherapies

Karolien Goffin and Ken Herrmann wrapped up Day 3 of the European Association of Nuclear Medicine (EANM) 2024, highlighting several exciting developments. A key focus was the transformative role of PSMA PET in managing prostate cancer, which has proven essential for both initial diagnoses and cases of biochemical recurrence and re-staging. The day featured top-rated abstracts and plenary session that underscored advancements in this field. Another significant discussion centered on #NuclearMedicine providing answers to questions in several clinical indications, particularly in #NETcancer as well as the key takeaway from the roundtable discussion regarding the readiness of current healthcare systems for #TargetedRadiopharmaceuticalTherapies. Looking ahead, Day 4 will focus on the groundbreaking trends shaping the future of nuclear medicine featuring the prestigious Marie Curie Lecture. #theranostics #Radiodiagnostic

#ITM celebrates National Pharmacy Week! 🎉 #PharmacyWeek is a time to recognize the invaluable contributions and powerful impact pharmacists make on healthcare. It is also an opportunity to raise awareness about the vital role they play in patient care. #NuclearMedicine departments across the nation rely on them to ensure doses are delivered every day, when and where they are needed. We applaud our #radiopharmacy colleagues for their dedication and making a difference in the life of patients! #Thankyou!

As promised, they’re back! 🎬 Join Karolien Goffin and Ken Herrmann as they share their insights on the exciting presentations from the plenary sessions and explore the scientific topics covered on Day 2 of the European Association of Nuclear Medicine (EANM) Association of Nuclear Medicine (2024) right from the CCH – Congress Center Hamburg. Watch the video below, where they highlight the prestigious EANM Marie Curie Award-winning abstract and delve into the current advancements in #theranostics. Discover how nuclear medicine physicians can become more actively involved in this rapidly expanding area of research and stay ahead of the curve! Join them again soon as they bring unique insights from Day 3, demonstrating how #NuclearMedicine can address clinical questions in oncology and beyond! #NETcancer #ProstateCancer #Radiodiagnostic #TargetedRadiopharmaceuticalTherapies

🏅 Congratulations to Dr. Julia Fricke from University Hospital Basel and her co-presenters for receiving the prestigious EANM Marie Curie Award last evening at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) 2024! They were recognized for their award-winning abstract: 🔬 Therapy with the somatostatin receptor antagonist DOTA-LM3 labeled with terbium-161: Interim results of the Phase 0 Study in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs), which will be presented later today at the #EANM2024 in Hamburg. ITM is proud that this award-winning abstract highlights research from our clinical development program focusing on GEP NETs (ITM-63). 👉 Don't miss the abstract presentation today: 📅 Date & Time: Sunday, October 20, 16:45-18:15 📍 Location: Hall Y1-Y3 Presenter: Dr. Julia Fricke, University Hospital Basel, Basel, Switzerland Presentation ID: OP-252 The EANM #MarieCurieAward honors outstanding research contributions in #NuclearMedicine, focusing on scientific excellence, innovation, and advancements in the field. Named after the pioneering scientist Marie Curie, the award celebrates groundbreaking research while fostering collaboration and knowledge exchange within the nuclear medicine community. #Innovation #CancerTherapies

Are you ready for an exciting journey? 👋 Over the next few days, join Karolien Goffin and Ken Herrmann as they share their daily highlights from the Annual Congress of the European Association of Nuclear Medicine (EANM) right from the vibrant city of Hamburg, Germany. 🚢 The congress, which has over 8,000 registered participants this year, promises to showcase the latest breakthroughs in oncology and nuclear medicine that could redefine the future of healthcare. Here's to a fantastic conference filled with inspiring presentations in nuclear medicine. Stay tuned for some incredible insights! 💡 They will return tomorrow with updates on key abstracts in neuroendocrine tumors, discussing plenary sessions 1 and 2, and much more. #EANM2024 #NETcancer #theranostics #ProstateCancer #Radiodiagnostic #TargetedRadiopharmaceuticalTherapies